The share of Russian drugs in the pharmaceutical market is expanding for the fifth year in a row. It currently stands for as much as 31.7 percent compared to 24.1 percent in 2012. The production of high-quality, domestically manufactured drugs in the key segments allows to make significant savings of budgetary funds and reduces the dependence of Russian health care system on the imports of medicines.
As of January 1, 2018, the share of Russian-made medicinal products in the List of Vital and Essential Drugs (VED) reached 84 percent (in 2012, it was 63 percent). Last year, the market for VED List medicines in the price category of up to 50 rubles increased by 2.1 percent in monetary terms and by 3.8 percent in physical terms compared to the same period of 2016.
In 2017, the exports of pharmaceuticals reached about 71 million US dollars in final prices and increased by 31.5 percent compared to the same period of 2016. All that occurs as the pharmaceutical industry keeps opening new production facilities. This includes the launch of Phase 1 of the Pharmasyntez-Nord plant and the official opening of Ozon Pharm plant in November 2017 to manufacture the medicines from VED List.
25 Russian competitive drugs were registered in 2017, and their total number since 2009 reached 70. The special investment contracts (SPICs) were signed with the world’s major pharmaceutical manufacturers, including Sanofi and AstraZeneca, and Geropharm, a Russian high-tech company, in accordance with the programs aimed at supporting the technology transfer and modernization of local manufacturing. Another SPIC is expected to be signed with NovaMedica (a part of RUSNANO investment portfolio).